Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1029)	5/18/1999 10:13:00 AM
From: Hal Barnett	Read Replies (1) \| Respond to of 3202

David and thread, Article on Venter in NY Times Science section today. nytimes.com An excerpt: "Both Morgan and Collins are putting good money after bad," Dr. Venter says, referring to Dr. Michael Morgan, the Wellcome Trust's executive for genome sequencing and Dr. Francis Collins, director of the N.I.H.'s part of the human genome project. "Their plan is not to finish the genome," he says, but rather to prevent him from obtaining the only sequence and locking it up with patent claims. An associate of Dr. Collins, Dr. Kathy Hudson, said that he remained "totally confident of the current human genome project strategy and that, "While Venter is certainly a fascinating personality, his every utterance does not seem to warrant a story in The New York Times." Copyright by New York Times 1999 Regards, Hal